CME vs NDAQ
CME Group and Nasdaq, side by side.
Prices and company dataas of yesterday's close
- CMEBuy moresales growth, past year8.9%
Two more analysts rate CME a buy than three months ago, and its sales grew 8.9% over the past year.
- NDAQBuy moresales growth, past year14%
Nasdaq's sales grew 14% over the past year, and the stock rose 17% over the past month, far more than other financial stocks (up 6%).
Percent return
- CME+17.67%
- NDAQ+26.53%
Nov 11, 2025 to Nov 11, 2026
Where they differ
- Company size: CME $95.4B, NDAQ $53.4B.
- Sales growth, 1 yr: CME +8.9%, NDAQ +14%. NDAQ is ahead.
- Price for $1 of next year's profit: CME $24, NDAQ $23. NDAQ is ahead.
- Profit per $1 of sales: CME 66¢, NDAQ 49¢. CME is ahead.
- Cash minus debt: CME −$1.52B, NDAQ −$8.91B. CME is ahead.
- Price change, 1 yr: CME +18%, NDAQ +27%. NDAQ is ahead. S&P 500 +12%.
- How much the price swings: CME 24%, NDAQ 26%. CME is ahead.
| Measure | CMECME Group | NDAQNasdaq |
|---|---|---|
| Price and returns | ||
| Price | $315.88 | $109.70 |
| Today | Best in this row: +2.20% | −0.29% |
| 1 month | +12.58% | Best in this row: +17.12% |
| 3 months | Best in this row: +22.38% | +15.84% |
| This year | Best in this row: +19.61% | +14.07% |
| 1 year | +17.67% | Best in this row: +26.53% |
| 5 years | Best in this row: +75.14% | +70.94% |
| From 52-week high | 0.0% | −0.3% |
| How much it swings (90 days) | Best in this row: 24% | 26% |
| Valuation | ||
| Market value | $95.4B | $53.4B |
| Price vs last year's earnings | Best in this row: 22.5× | 27.9× |
| Price vs next year's expected earnings | 23.6× | Best in this row: 23.4× |
| Price vs earnings, adjusted for growth | 2.42× | Best in this row: 1.30× |
| Price to sales | 15.7× | Best in this row: 10.3× |
| Price vs cash it brings in | Best in this row: 25.3× | 26.3× |
| Company value vs operating profit | 22.5× | Best in this row: 19.6× |
| Price vs earnings, against its own past (0 = cheapest) | Best in this row: 63 | 96 |
| Growth | ||
| Revenue growth, 1 year | +8.9% | Best in this row: +13.7% |
| Revenue growth a year, last 3 years | +9.0% | Best in this row: +13.6% |
| Earnings per share growth, last year | +18.5% | Best in this row: +50.8% |
| Earnings per share growth expected next year | +6.8% | Best in this row: +14.5% |
| Profitability | ||
| Kept from sales after making the product | 100.0% | 100.0% |
| Kept as operating profit | Best in this row: 66.2% | 49.0% |
| Kept as final profit | Best in this row: 63.3% | 36.0% |
| Kept as spare cash | Best in this row: 62.3% | 39.1% |
| Profit on shareholders' money | 16.1% | Best in this row: 17.3% |
| Profit on all money put in | Best in this row: 12.6% | 10.8% |
| Balance sheet | ||
| Net cash (cash minus debt) | Best in this row: −$1.52B | −$8.91B |
| Debt for each $1 of shareholders' money | Best in this row: 0.15× | 0.77× |
| Short-term assets per $1 of bills due | Best in this row: 1.02× | 1.00× |
| Dividend yield | Best in this row: 3.71% | 1.16% |
| Share of profit paid as dividends | 93% | Best in this row: 34% |
| Our readPro | ||
| Our call | Buy more | Buy more |
| Why | Two more analysts rate CME a buy than three months ago, and its sales grew 8.9% over the past year. | Nasdaq's sales grew 14% over the past year, and the stock rose 17% over the past month, far more than other financial stocks (up 6%). |
| Where the price sits | in the full report | in the full report |
| Our overall score (out of 100) | 59 | Best in this row: 66 |
| Our value score | 49 | Best in this row: 51 |
| Our growth score | 56 | Best in this row: 71 |
| Our quality score | Best in this row: 87 | 80 |
| Our price trend score | 48 | Best in this row: 61 |
| Earnings and analysts | ||
| Analyst consensus | Buy | Buy |
| To average analyst target | −1.9% | Best in this row: +6.2% |
| Average analyst target | $310.00 | $116.53 |
| Analysts rating it a buy | 53% | Best in this row: 78% |
| Buy ratings added, 3 months | Best in this row: +2 | 0 |
| Analysts covering | 12 | 16 |
NDAQ: faster growth at a lower P/E
Our pick of these: Nasdaq
Sales growth +13.7% vs +8.9%
CME +8.9%, NDAQ +13.7%.Forward P/E per point of sales growth 1.71 vs 2.64
CME 2.64, NDAQ 1.71.+6.2% to the average analyst target, vs −1.9%
CME −1.9%, NDAQ +6.2%.Where it loses: CME has wider profit margins, 66.2% vs 49.0%
Cover this stock to see the full report
The call, its reasons and what would change it are free for everyone. The price zones, the whole brief and how the call has moved come with covering a stock. Use one of your three covered slots, or go Pro for every stock.
Prices as of yesterday, 3:59 PM ET. A view, not advice.